PET scan for T-NK cell lymphoma
Part of Cancer, Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This trial uses a special PET scan to see how well treatment works for T-NK cell lymphoma. The scan looks for a protein called granzyme B, which may help predict how the disease will respond and what the outlook might be.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with T-NK cell lymphoma.
- You are either newly diagnosed and have not had treatment, or your lymphoma has come back and you are about to start immunotherapy.
- The doctor has all your medical records and follow-up information.
- You are willing to sign a consent form to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses artificial intelligence to analyze PET/CT scans of people with T-NK cell lymphoma. The goal is to see if the AI can help doctors better diagnose this rare cancer, predict how well treatment will work, and forecast long-term outcomes.
This trial studies whether special imaging with PET/MR can help stage (find the extent of) and evaluate treatment effectiveness in people newly diagnosed with NK/T-cell lymphoma. It may help doctors choose the right treatment plan and track how well therapy is working.
This trial uses PET scans and EBV DNA levels to personalize treatment for patients with early-stage nasal NK/T cell lymphoma. It aims to reduce side effects by adjusting therapy based on how well the cancer responds.
This trial tests a new type of PET scan (Granzyme B-PET) to see if it can predict how well immunotherapy will work for people with triple-negative breast cancer that has spread. If it works, doctors might be able to tell sooner whether treatment is helping.
This trial uses a special PET scan to see if a protein called Granzyme B can predict how well immunotherapy will work for people with DLBCL. It aims to help doctors know earlier if treatment is effective.
This trial tests a combination of the immunotherapy drug tislelizumab with two chemotherapy drugs (gemcitabine and peraspartase) for people with newly diagnosed stage I or II NK/T-cell lymphoma. The goal is to see if this combination works well and is safe.
Hear when a new T-NK Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.